A short teaser points to UT Health San Antonio work on what GLP-1 medications might do outside weight and metabolic health. Few details are given.
Recap by typeshit. Post by @thelongsom on Instagram.
A retrospective study in Cureus looks back at how well once-weekly semaglutide worked, and how safe it was, for teenagers with obesity.
Presented at Sleep Europe 2026, both trials found retatrutide lowered the apnea-hypopnea index more than placebo, including in people with type 2 diabetes.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Mubadala Bio's Hamad Almarzooqi says the drugs will be contract-manufactured in the UAE and shipped across the region and beyond. He announced it at the Abu Dhabi Future Health Summit.
Loading…